More than 2 billion people in the world are infected
|
|
- Daniel Jordan
- 5 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2: Year Follow-up Study of a Prospective Randomized Trial of Hepatitis B Vaccinations Without Booster Doses in Children MAN FUNG YUEN,* WEI LING LIM, ANNIE ON ON CHAN,* DANNY KA HO WONG,* SIMON SIU MAN SUM,* and CHING LUNG LAI* *Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong; and Department of Health, Hong Kong, China Background & Aims: The long-term immunogenicity and efficacy of hepatitis B virus (HBV) vaccination remain to be defined. We aimed to examine the long-term immunogenicity and efficacy of HBV vaccination with 3 different regimens over 18 years of follow-up. Methods: A total of 318 Chinese subjects receiving 3 different regimens of HBV vaccination (2-dose recombinant vs. 3-dose recombinant vs. 3-dose plasma-derived vaccines) without receiving a booster dose were recruited. The HBV serologic markers, including hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-hbs), and antibody to hepatitis B core antigen (anti- HBc), were determined at yearly follow-up. After 18 years, 88 subjects were still being followed up. Results: Compared with subjects receiving the 2-dose regimen, subjects receiving the 3-dose regimens had a significantly higher geometric mean titer of anti-hbs and a higher proportion had anti-hbs titers >10 miu/ml during the 18 years of follow-up. There were no differences in these 2 parameters between subjects receiving the 3-dose recombinant and subjects receiving the 3-dose plasma-derived vaccines. A total of 88 anamnestic responses were documented in 70 subjects (8 with initial anti-hbs titers <100 miu/ml at 12 months and 7 with anti-hbs titers <10 miu/ml before the anamnestic responses). No subject became positive for HBsAg. Three subjects had benign breakthrough HBV infection without leading to chronicity indicated by isolated anti-hbc positivity. Conclusions: There was less long-term immunogenicity associated with the 2-dose regimen when compared with the 3-dose regimens of HBV vaccination. Because of the highly effective anamnestic responses, a booster dose was not necessary at least up to 18 years after the primary vaccination. More than 2 billion people in the world are infected with hepatitis B virus (HBV). Of these, about 400 million are chronic hepatitis B carriers. 1,2 It is estimated that there will be more than 50 million new HBV infections every year if there are no effective vaccination programs. 3 Universal vaccination is the most effective method to control HBV infection worldwide. A national HBV vaccination program has also been shown to effectively reduce the occurrence of hepatocellular carcinoma in Taiwan. 4 To date, universal vaccination programs have been implemented in about 154 countries around the world. 5 The most important issue concerning HBV vaccination is its long-term efficacy in preventing HBV infection. Whether booster doses of vaccine are necessary to maintain long-term immunity is still under debate. Most follow-up studies suggest that booster doses are probably not necessary in immunocompetent subjects because of the effective secondary (anamnestic) responses generated from memory B cells, 6 16 with the longest follow-up study from Taiwan reporting a 14-year period of follow-up after the primary vaccination. 8 According to the recommendations from the European Consensus Group on Hepatitis B Immunity in 2000, 9 continuous longterm monitoring is required to determine whether an HBV carrier state develops after 15 years of primary vaccination. We have previously reported a 5-year and a 12-year long-term follow-up study on the efficacy of recombinant and plasma-derived vaccines without booster doses in children. 6,7 The aim of the present extended study was to examine the long-term immunogenicity and efficacy of HBV vaccination at 18 years of follow-up. Subjects and Methods Subjects Close relatives of HBV carriers were recruited into the trial between November 1984 and February The subjects were between 3 months and 11 years of age. They were screened for hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-hbs), and antibody to hepatitis B core antigen (anti-hbc) by radioimmunoassays (AUS- Abbreviations used in this paper: anti-hbc, antibody to hepatitis B core antigen; anti-hbs, antibody to hepatitis B surface antigen; GMT, geometric mean titer; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen by the American Gastroenterological Association /04/$30.00 PII: /S (04)
2 942 YUEN ET AL. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 2, No. 10 RIA II, AUSAB, and COBAS, respectively; Abbott Laboratories, North Chicago, IL). Inclusion criteria were as follows: (1) serum negative for HBsAg, anti-hbs, and anti-hbc; (2) serum alanine aminotransferase level 50 U/L; (3) no history of receiving hepatitis B immunoglobulin within 4 months of recruitment; and (4) no history of serious systemic illnesses or allergy. Patients or guardians were given full explanations of the study before written consent was obtained. Vaccination Protocol Children were randomized into 3 groups receiving different regimens of vaccination. Randomization was performed by computer-generated assignment. Children in group 1 received two 5- g doses of recombinant DNA yeast vaccine (H-B-VAX II; Merck Sharp & Dohme, West Point, PA) at 0 and 1 months; children in group 2 received three 5- g doses of H-B-VAX II at 0, 1, and 6 months; and children in group 3 received three 10- g doses of plasma-derived vaccine (H-B-VAX) at 0, 1, and 6 months. Children who did not develop anti-hbs and those with an anti-hbs titer of 10 miu/ml at 8 months were given a booster dose at months. These subjects were excluded from the analyses. No booster dose was given to any other subject during follow-up. Subject Monitoring All of the subjects had a scheduled follow-up at yearly intervals until the time of this report. Subjects who did not attend the follow-up were recalled to attend the follow-up in the subsequent year. Sera were taken at every follow-up for determination of HBsAg, anti-hbs, and anti-hbc titers. Subjects were considered to have HBV infection if at least 2 consecutive sera were positive for anti-hbc, HBsAg, or both. Anamnestic Response Because the anti-hbs titers of all the vaccinated subjects decreased within 12 months of the first dose of vaccination, a significant increase in the anti-hbs titers in subjects not receiving booster doses at the subsequent follow-up implies a generation of secondary (anamnestic) response after exposure to HBV. Using the criteria defined in our previous reports, 6,7 an anamnestic response was defined by the following criteria. (1) For subjects with anti-hbs titers that decreased after 12 months to an undetectable level or levels 10 miu/ ml, the increase in the anti-hbs titers should be 100 miu/ml. (2) For subjects with anti-hbs titers 10 miu/ml, the increase in the anti-hbs titers should be more than 2 times the previous values with the absolute levels of 200 miu/ml. Statistical Analysis The statistical analyses were performed with the 2-tailed Student t test for the continuous variables, 2 test, and Fisher exact test for categorical variables. Correlation between variables was performed by a correlation test with the Pearson coefficient. The skewed anti-hbs titers were transformed into logarithmic values for statistical analyses. Results Demographics A total of 318 subjects were randomized into the 3 groups. The number, sex, and mean age of these subjects in each group at study entry are listed in Table 1. Eleven subjects (6 in group 1, 2 in group 2, and 3 in group 3) had an anti-hbs titer 10 miu/ml at 8 months and were given a booster dose at months. These subjects were excluded from the subsequent analyses. There were no differences among the 3 groups in the percentages of patients who did not have anti-hbs titers 10 miu/ml at 8 months (P NS for all). After 18 years, 88 of these subjects were still being followed up. Geometric Mean Titer The geometric mean titer (GMT) and the proportions of subjects with an anti-hbs titer 10 miu/ml in different groups at the first, fifth, 10th, and 15th years of follow-up are listed in Table 2. The anti-hbs titer at 12 months correlated positively with the anti-hbs titers in all of the subsequent follow-ups in the whole study population (r values ranging from 0.67 to 0.88; P for all). As reported in our previous study, subjects in groups 2 and 3 had a significantly higher GMT than subjects in group 1 in the first 12 years of follow-up. 7 In the present study, subjects in group 2 continued to have a significantly higher GMT compared with subjects in group 1 throughout the subsequent follow-up to 18 years. Subjects in group 3 also had a significantly higher GMT compared with subjects in group 1 at the 17th year of follow-up (a trend toward significance at the 16th year Table 1. Demographic Data of the 318 Patients in the Study Group 1 Group 2 Group 3 No. of patients Male/female 48/57 52/54 48/59 Mean age, yr (range) 5.4 ( ) 5.6 ( ) 5.3 ( ) NOTE. The male-to-female ratio at the 18th year of follow-up was 39/49 (group 1, 11/14; group 2, 15/15; group 3, 13/20). There were no significant differences in the sex ratios in each respective group at baseline and at the last follow-up.
3 October 2004 LONG TERM FOLLOW UP OF HBV VACCINATION 943 Table 2. Immunogenicity of the 3 Groups of Subjects During Follow-up Follow-up (yr) Group 1 No. of subjects titer 10 miu/ml (%) 88 (88.8) a,b 54 (75) 37 (71.2) c 19 (54.3) 19 (52.8) d 14 (50) e,f 12 (48) g GMT (miu/ml) 83 h 47 h 36.0 i,j 24.9 k 11.0 l,m 8.8 n,o 10.0 p Group 2 No. of subjects titer 10 miu/ml (%) 97 (98) a 55 (87.3) 45 (81.8) 27 (73.0) 30 (81.1) d 26 (76.5) e 22 (73.3) g GMT (miu/ml) 1085 h 131 h 80.5 i 47.5 k 63.6 l 50.1 n 35.3 p Group 3 No. of subjects titer 10 miu/ml (%) 101 (97.1) b 54 (84.3) 51 (91.1) c 23 (63.9) 32 (72.7) 33 (73.3) f 19 (57.6) GMT (miu/ml) 858 h 250 h 89.1 j m 29.0 o 20.3 a P 0.018; b P 0.026; c P 0.012; d P 0.01; e P 0.03; f P 0.043; g P 0.05; h P 0.001; i P 0.005; j P 0.028; k P 0.009; l P 0.002; m P 0.07; n P 0.005; o P 0.02; p P of follow-up; P 0.07). There were no differences in the GMT between subjects in group 2 and subjects in group 3 throughout the 18 years of follow-up. Protective Anti-HBs Titer Groups 2 and 3 had higher proportions of subjects with anti-hbs titers 10 miu/ml (defined as the protective titer) 17 compared with group 1 throughout the follow-up period (Table 2). These differences in the proportions of subjects with protective anti-hbs titers were statistically significantatthe first, 16th, 17th, and 18th years of follow-up when group 2 was compared with group 1 and at the first, 10th, and 17th years of follow-up when group 3 was compared with group 1 (Table 2). There were no differences in the proportions of subjects with protective anti-hbs titers between group 2 and group 3 throughout the 18 years of follow-up. Anamnestic Response During the 18 years of follow-up, 70 patients had at least one anamnestic response (26 in group 1, 23 in group 2, and 21 in group 3). There were a total of 88 episodes of anamnestic responses in these 70 patients. Fifty-six subjects had only one episode of anamnestic response; 11 subjects, 2 subjects, and one subject had 2, 3, and 4 episodes, respectively. The exact increase in anti-hbs titers of all the anamnestic responses are shown in Figure 1. Among these 70 subjects, 8 subjects (all in group 1) (11.4%) had anti-hbs titers 100 miu/ml at 12 months. In addition, 7 episodes of the anamnestic responses were in subjects with the preceding anti-hbs titers of 10 miu/ml (3 with undetectable anti-hbs levels and 4 with anti-hbs levels ranging from 1 to 9 miu/ml) (Figure 1). HBV Infection Thirty-four of 88 patients (38.6%) had anti- HBs titers 10 miu/ml at the last follow-up. However, no subject became positive for HBsAg. Three subjects became weakly positive for anti-hbc. One subject in group 2 became positive for anti-hbc with Figure 1. The anamnestic responses of (A) 63 subjects with anti-hbs titers 10 miu/ml and (B) 7 subjects with anti-hbs titers 10 miu/ml.
4 944 YUEN ET AL. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 2, No. 10 an anti-hbs titer of 36 miu/ml at the ninth year of follow-up (at the age of 12.0 years). He was persistently positive for anti-hbc throughout the subsequent follow-up. The second subject (in group 1) became positive for anti-hbc with an anti-hbs titer of 22 miu/ml at the 11th year of follow-up (at the age of 15.3 years). The third subject (in group 3) became positive for anti-hbc with an anti-hbs titer of 76 miu/ml at the 17th year of follow-up (at the age of 18.3 years). The latter 2 subjects did not attend follow-up afterward, and their subsequent anti-hbc status could not be determined. Discussion According to our previous report with 12 years of follow-up, there are no differences in the long-term immunogenicity (as measured by the GMT and the proportion of subjects with an anti-hbs titer 10 miu/ml) and efficacy of HBV vaccination between the 3-dose regimens of recombinant vaccine (group 2) and plasma-derived vaccine (group 3). 7 Although the long-term immunogenicity for subjects receiving 2 doses of recombinant vaccine (group 1) was lower when compared with those in groups 2 and 3, there were no differences in the protective efficacy between the 3 groups. The present study extended the follow-up to 18 years. To our knowledge, this is the longest follow-up study on the immunogenicity and protective efficacy of the HBV vaccines. Although only 88 patients attended the last follow-up at the 18th year, the results of the present study were unlikely to be biased because all of the subjects were family members of patients with chronic hepatitis B and the 2 major reasons for not attending follow-up were emigration from Hong Kong and inability to attend follow-up because of daytime working duties. In addition, there were no differences in the sex ratios of each group at baseline and at the last follow-up (Table 1). Similar to our previous report at 12 years of follow-up, 7 3-dose regimens are preferable to 2-dose regimens to achieve better long-term immunogenicity (Table 2), although the extra cost for one more dose of vaccine may be an important consideration for developing countries. Anti-HBs titers wane with time after the primary vaccination. The present study showed that the anti-hbs titers at 12 months after primary vaccination correlated positively with the anti-hbs titers at each year of subsequent followup. This finding is in accordance with the study by Theppisai et al. 18 The higher the anti-hbs titers achieved after the primary vaccination, the better the long-term immunogenicity. A more important issue is whether immunogenicity can be effectively restored in subjects with anti-hbs titers lower than the arbitrarily defined protective level (anti-hbs titer 10 miu/ml) without a booster dose. In the present study, anamnestic responses were observed in 70 subjects with a total of 88 episodes (Figure 1). There were 2 important issues concerning these anamnestic responses. Firstly, 8 subjects with anamnestic responses had anti-hbs titers 100 miu/ml at 12 months after the primary vaccination. Secondly, 7 episodes of anamnestic responses were from subjects with anti-hbs titers 10 miu/ml. Therefore, anamnestic responses could be of significant magnitude even when the initial anti-hbs titers at 12 months were not particularly high and, more importantly, even when the subsequent anti-hbs titers had decreased to 10 miu/ml. The anamnestic responses observed in our Chinese subjects may be partly related to the fact that they had a higher risk and frequency of contracting HBV from their HBsAgpositive family members. However, we believe that our results are applicable to subjects in western countries where the general incidence of HBV infection is low. It has been shown that remarkable immune responses can be obtained in vaccinated western populations with unprotective anti- HBs titers when subjects are given purified nonadsorbed HBsAg. 19 The reason may be that the number of memory B cells does not decrease with time despite the decline of the antibody level. 20 Braito et al. also showed that in western populations, decline of anti-hbs level does not necessarily mean a loss of immunity. 21 According to various studies, anamnestic responses can be generated within 3 5 days of exposure of HBV, 19,22,23 although it has also been suggested that the 3- to 5-day period of delay may provide an opportunity for infection to occur. In the present study, no subject tested positive for HBsAg. Only 3 subjects became weakly positive for anti-hbc. This indicated transient benign breakthrough infections without resulting in the chronic carrier state. According to a Taiwan study with 14 years of follow-up, only 2 of 258 vaccinated children who had not received a booster dose became positive for anti- HBc without HBsAg positivity. 24 The low infective rate of HBV in the present study is of particular importance for 2 reasons. Firstly, the study subjects were at a higher risk of contracting HBV because they were all close relatives of HBV carriers. Secondly, 35 subjects (39.8%) had anti-hbs titers 10 miu/ml at the last follow-up (Table 2). HBV vaccination even without a booster dose is effective in prevention of HBV infection for at least up to 18 years. In conclusion, in subjects who had developed an adequate anti-hbs response (i.e., 10 miu/ml) after the primary vaccination, a booster dose was not necessary to prevent HBV infection at least up to 18 years because of the highly effective anamnestic responses despite the decline in anti-
5 October 2004 LONG TERM FOLLOW UP OF HBV VACCINATION 945 HBs titers. This appears to be true irrespective of the vaccination regimens or the types of vaccines. References 1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337: Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001;1: Farrell J, Dienstag J. Epidemiology and prevention of hepatitis B virus infection. In: Lai CL, Locarnini S, eds. Hepatitis B virus. London, England: International Medical Press, 2002: Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336: Namgyal P. Impact of hepatitis B immunization in Europe and worldwide. European Association for the Study of the Liver. Consensus Conference on Hepatitis B. Geneva, Switzerland, September 12 14, Lai CL, Wong BCY, Yeoh EK, Lim WL, Chang WK, Lin HJ. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology 1993;18: Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine without booster doses in children. Hepatology 1999;29: Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003;187: Banatvala JE, Van Damme P. Hepatitis B vaccine do we need boosters? J Viral Hepat 2003;10: Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, Wang SS, Li YP, Zhang KL. Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children: a 12-year follow-up study. World J Gastroenterol 1999;5: Liu HB, Meng ZD, Ma JC, Han CQ, Zhang YL, Xing ZC, Zhang YW, Liu YZ, Cao HL. A 12-year cohort study on the efficacy of plasmaderived hepatitis B vaccine in rural newborns. World J Gastroenterol 2000;6: Ayerbe MC, Perez-Rivilla A, ICOVAHB group 1. Assessment of longterm efficacy of hepatitis B vaccine. Eur J Epidemiol 2001;17: Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999;29: Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995;126: Coursaget P, Leboulleux D, Soumare M, le Cann P, Yvonnet B, Chiron JP, Coll-Seck AM, Diop-Mar I. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994;21: Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993;17: Centers for Disease Control. Recommendation of the immunization practices advisory committee. Recommendations for protection against viral hepatitis. MMWR 1985;34: Theppisai U, Thanuntaseth C, Chiewsilp P, Siripoonya P. Longterm immunoprophylaxis of hepatitis B surface antigen positive mothers using plasma derived vaccine. Asia Oceania J Obstet Gynaecol 1989;15: Dentico P, Crovari P, Lai PL, Ponzio F, Safary A, Pellegrino A, Meurice F, Di Pasquale A, Tornieporth N, Volpe A, Icardi G. Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres. Vaccine 2000;20; West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996;14: Braito A, Bianchini AM, Mattei C, Benci A, Marri D, Toti M. Decline of HBsAg antibodies after immunization with hepatitis B vaccines and after natural infection. Boll Ist Sieroter Milan ;70: Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. J Med Virol 1988;24: Wismans PJ, Van Hattum J, Mudde GC, Endeman HJ, Peol J, de gast GC. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol 1989;8: Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003;187: Address requests for reprints to: Ching-Lung Lai, M.D., Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam Road, Hong Kong, China. hrmelcl@hkucc.hku.hk; fax: (852)
Hepatitis B virus (HBV) infection is an important. Brief Communication
Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationAlthough substantial progress has been made in
VIRAL HEPATITIS Waning Immunity to Plasma-Derived Hepatitis B Vaccine and the Need for Boosters 15 Years After Neonatal Vaccination Chun-Yi Lu, 1 Bor-Luen Chiang, 1,2 Wei-Kuang Chi, 3 Mei-Hwei Chang, 1
More informationAre booster immunisations needed for lifelong hepatitis B immunity?
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support
More informationUniversal hepatitis B (HB) immunization has
Determination of Immune Memory to Hepatitis B Vaccination Through Early Booster Response in College Students Chyi-Feng Jan, 1,2 Kuo-Chin Huang, 1 Yin-Chu Chien, 3 Donald E. Greydanus, 2 H. Dele Davies,
More informationObservational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children Hilton Whittle, Shabbar Jaffar, Michael Wansbrough, Maimuna Mendy, Uga Dumpis, Andrew Collinson,
More informationHepatitis B surface antigen HBsAg Hepatitis B e antigen HBeAg 1) B
292 14 4 B Effects of the Vaccination Against Hepatitis B Virus for All Infants in Taiwan Chang-Kuen Tien, Nobutaka Kurihara, Hiroyuki Yanagisawa and Osamu Wada (Hygiene and Preventive Medicine, Saitama
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDownloaded from:
Whittle, H; Jaffar, S; Wansbrough, M; Mendy, M; Dumpis, U; Collinson, A; Hall, A (22) Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ, 325
More informationChing-Wen Wang, Li-Chieh Wang, Mei-Hwei Chang,* Yen-Hsuan Ni, Huey-Ling Chen, Hong-Yuan Hsu, and Ding-Shin Chen
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Dec. 2005, p. 1442 1447 Vol. 12, No. 12 1071-412X/05/$08.00 0 doi:10.1128/cdli.12.12.1442 1447.2005 Copyright 2005, American Society for Microbiology. All
More informationHumoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster Years after Neonatal Immunization
MAJOR ARTICLE Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 15 18 Years after Neonatal Immunization Chun-Yi Lu, 1 Yen-Hsuan Ni, 1 Bor-Luen Chiang, 1 Pei-Jer Chen, 2 Mei-Hwei Chang,
More informationIncomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees
Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees Yin-Chu Chien, 1 Chyi-Feng Jan, 2 Chun-Ju Chiang, 3 Hsu-Sung
More informationORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university
Malaysian J Pathol 2018; 40(3) : 295 302 ORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university Siti Norlia OTHMAN, Zetti ZAINOL
More informationEvidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand
Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand http://waipra.blogspot.com/2011/02/9.html Burden of disease in Thailand Liver diseases
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationC hronic hepatitis B (CHB) virus infection affects more
161 HEPATITIS Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications MF Yuen, HJ Yuan, D KH Wong, J CH Yuen, WM Wong, A OO Chan, B CY Wong, KC Lai, CL Lai... See end of article
More informationuniversal vaccination
Vol. 21No. 2149 8 HB B universal vaccination Blumberg HBs B 40 B HBV HBV HBV HBs WHO 1992 HBV B HB universal vaccination 1997 HB universal vaccination HBV high risk HBV universal vaccination B HBV universal
More informationReceived 30 May 2004/Returned for modification 6 August 2004/Accepted 12 August 2004
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2004, p. 5036 5040 Vol. 42, No. 11 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.11.5036 5040.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationLong term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers
Archives of Disease in Childhood 1997;77:F47 F51 F47 Viral Hepatitis Research Unit Chulalongkorn University Hospital, Bangkok, Thailand Y Poovorawan Department of Paediatrics S Sanpavat S Chumdermpadetsuk
More informationHepatitis B (HBV) vaccine: need for a booster injection? VHPB, Kyiv 2004
Hepatitis B (HBV) vaccine: need for a booster injection? VHPB, Kyiv 2004 Information for the Development of Immunization Policy 2002 update (WHO/V&B/02.28, printed: March 2003) The priorities for hepatitis
More informationThe Hepatitis B Vaccine: What Went Wrong?
The Hepatitis B Vaccine: What Went Wrong? By F. Edward Yazbak, MD, FAAP On Dec. 23, 2005, the Centers for Disease Control and Prevention (CDC) published a Morbidity and Mortality Weekly Report (1) in which
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationLong-term Antibody Response and Immunologic Memory in Children Immunized with Hepatitis B Vaccine at Birth
endocrine profile and factors indicating neurogenic precocity in Indian children. J Pediatr Endocrinol Metab 2002; 15: 1173-1181. 18. Avila NA, Shawker TS, Jones JV, Cutler GB Jr, Merke DP. Testicular
More informationsubjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDetermination of Hepatitis B Surface Antibody Titer in Vaccinated Children with Major Thalassemia in Kerman-Iran
Determination of Hepatitis B Surface Titer in Vaccinated Children with Major Thalassemia in Kerman-Iran Ali Asghar Vahidi 1, Majid Varesvazirian 1, Ayeh Shamsadini 1, Sadollah Shamsadini 2 1 Department
More informationEpidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur
Epidemiology of Hepatitis B in sub-saharan Africa 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000
More informationEstimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants
ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationAN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS
AN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS Thosporn Vimolket 1 and Yong Poovorawan 2 1 Department
More informationHEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN
UNIVERSAL HEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN MEI-HWEI CHANG, M.D., CHIEN-JEN CHEN, SC.D., MEI-SHU LAI, M.D., HSU-MEI HSU, M.P.H., TZEE-CHUNG WU,
More informationAntiviral Therapy 14:
Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,
More informationKey words: HBV, Taiwan, epidemiology, vaccination program, hepatitis B vaccine
Original Article 521 Forecasting the Declining Rate of Chronic Hepatitis- Carrier Status at a Taiwanese University: Twenty Years after Implementation of an Universal HV Vaccination Program in Taiwan Fu-Hsiung
More informationTwo Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies
GASTROENTEROLOGY 2007;132:1287 1293 Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies YEN HSUAN NI,* LI MIN HUANG,* MEI HWEI CHANG,* CHUNG JEN YEN,
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationSummary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background:
Prepared by: TV Murphy, MD, September 16, 2016 Summary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background: The primary
More informationInterferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1
Title Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1 Author(s) Hui, CK; Yuen, MF; Sablon, E; Chan, AOO; Wong, BCY; Lai, CL Citation Journal Of Infectious
More informationFor the additional vaccination phase
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes
Hepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes VHPB meeting, Seville, 11-12 March 2004 Immunization programmes Programmes protect
More informationPERSISTENCE OF ANTI-HBs ANTIBODIES IN HEALTHY IRANIAN CHILDREN VACCINATED WITH RECOMBINANT HEPATITIS B VACCINE AND RESPONSE TO A BOOSTER DOSE
PERSISTENCE OF ANTI-HBs ANTIBODIES IN HEALTHY IRANIAN CHILDREN VACCINATED WITH RECOMBINANT HEPATITIS B VACCINE AND RESPONSE TO A BOOSTER DOSE A. Jafarzadeh * and S. M. A. Sajjadi Department of Microbiology
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationPathological Features and Prognosis in Chronic Hepatitis B Virus Carriers
The Journal of International Medical Research 2011; 39: 71 77 Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers ZH LU, W CHEN, ZC JU, H PEI, XJ YANG, XB GU AND LH HUANG Department
More informationYuen, MF; Sablon, E; Yuan, HJ; Hui, CK; Wong, DKH; Doutreloigne, J; Wong, BCY; Chan, AOO; Lai, CL
Title Author(s) Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus Yuen, MF; Sablon, E; Yuan,
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationIMMUNOGENICITY OF PLASMA DERIVED V ACCINE IN ETHIOPIAN HOSPITAL PERSONNEL. Hailu Kefenie.,MD, Bekure Des!A. & Almaz Abebe..,MSc
IMMUNOGENICITY OF PLASMA DERIVED V ACCINE IN ETHIOPIAN HOSPITAL PERSONNEL Hailu Kefenie.,MD, Bekure Des!A. & Almaz Abebe..,MSc ABSTRACT: To study the immunogenicity of plasma derived hepatitis B vaccine,
More informationHBsAg(+) mothers is a transient
Perinatal HBV viremia in newborns of HBsAg(+) mothers is a transient phenomenon that does not necessarily imply HBV infection transmission Vana Papaevangelou (Greece) National and Kapodistrian University
More informationS ince effective vaccines against hepatitis B became
1499 LIVER Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan H-Y Hsu, M-H Chang, Y-H Ni, H-L Chen... See end of article for authors
More informationHEPATITIS B: are escape mutants of concern?
VACCINATION: AN EVOLUTIONARY ENGINE FOR SPECIES? Fondation Mérieux Conference Centre Veyrier-du-Lac, France November 25-27, 2013 HEPATITIS B: are escape mutants of concern? Alessandro ZANETTI Department
More informationImmunogenicity and saf ety of recombinant hepatitis B vaccine ( HG- II) in healthy adults according to months v accination s chedule
: 58 1 2000 B (HG- II) : 0-1- 2, *, * = A bs tra c t= Immunogenicity and saf ety of recombinant hepatitis B vaccine ( HG- II) in healthy adults according to 0-1- 2 months v accination s chedule Ok Jae
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationMA PERINATAL HEPATITIS B PREVENTION PROGRAM
MA PERINATAL HEPATITIS B PREVENTION PROGRAM Massachusetts Department of Public Health Immunization Program MIAP 2016 1 1 Presenter Disclosure Information I, Theodora Wohler, have been asked to disclose
More informationAge-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan,
Age-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan, 1976 2005 LONG-TENG LEE, HSIAO-YUAN HUANG, KUO-CHIN HUANG, CHING-YU CHEN, AND WEN-CHUNG LEE PURPOSE: Hepatocellular carcinoma
More informationHepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.
Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. Vana Papaevangelou (Greece) National and Kapodistrian University of Athens Chang SemFNM
More informationPrevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy
Vaccine 24 (2006) 3095 3099 Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy Sudawan Siriaksorn a, Thanyawee
More informationLong-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease
Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay
More informationSlides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.
Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,
More informationGuideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients
Guideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients WOMEN AND CHILDREN S DIRECTORATE ACUTE SERVICES DIVISION GUIDELINES TITLE Guideline on
More informationMin Weng, Wei-Zheng Zeng *, Xiao-Ling Wu, Yong Zhang, Ming-De Jiang, Zhao Wang, De-Jiang Zhou and Xuan He
Weng et al. Virology Journal 2013, 10:277 RESEARCH Open Access Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis
More informationY. Xiang*, P. Chen*, J.R Xia and L.P. Zhang
A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies Y. Xiang*, P. Chen*,
More informationWhat have we learned from HBV clinical cohorts?
PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationHepatitis B and the Need for a Booster Dose
VACCINES INVITED ARTICLE Stanley Plotkin, Section Editor Hepatitis B and the Need for a Booster Dose Elke Leuridan and Pierre Van Damme Centre for the Evaluation of Vaccination, Vaccine and Infectious
More informationSerological Markers in Chimpanzees
INFECTION AND IMMUNITY, May 1979, p. 352-356 Vol. 24, No. 2 0019-9567/79/05-0352/05$02.00/0 Hepatitis B e-antigen and Its Correlation with Other Serological Markers in Chimpanzees CHUNG-MEI LING,* ISA
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationPrevention and control of hepatitis B with combined vaccines, and birth dose vaccination
Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination Prof. Yong Poovorawan Center of Excellence in Clinical Virology Faculty of Medicine Chulalongkorn University The
More informationImmunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules
Infection (2010) 38:269 273 DOI 10.1007/s15010-010-0031-2 CLINICAL AND EPIDEMIOLOGICAL STUDY Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules S. Agladioglu
More informationSeroprotection after Hepatitis B Vaccination among Newborn Infants: a Review
Center for Global Health Seroprotection after Hepatitis B Vaccination among Newborn Infants: a Review Rania Tohme, MD, MPH Team Lead Global Immunization Division, US CDC Viral Hepatitis Prevention Board
More informationDevelopment of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationThe Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections
The Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections Neil S. Silverman, M.D. Center for Fetal Medicine and Women s Ultrasound Clinical Professor, Obstetrics/Gynecology David Geffen
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHepatitis B virus (HBV) infection is a global. Chronic Hepatitis B Infection in Adolescents Who Received Primary Infantile Vaccination
Chronic Hepatitis B Infection in Adolescents Who Received Primary Infantile Vaccination Tzu-Wei Wu, 1 * Hans Hsienhong Lin, 2,3 * and Li-Yu Wang 1,4 Hepatitis B virus (HBV) infection is a global health
More informationHepatitis B vaccination worldwide: Lessons learnt and the way forward
Hepatitis B vaccination worldwide: Lessons learnt and the way forward VHPB Russia meeting Oct 2018 Pierre Van Damme MD, PhD History Hepatitis B vaccines have been available since early 1980 s First recommended
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationHBV in New Zealand Community HBV screening to long-term follow-up
HBsAg+ icteric hepatitis (n) % anti-hbcore+ 26/9/214 HBV in New Zealand Community HBV screening to long-term follow-up John Hornell, CEO, A registered charitable trust whose mission is: To improve health
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More information2018 Adult Immunization Schedule
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases 2018 Adult Immunization Schedule National Adult Immunization Coordinators Partnership Quarterly Meeting
More informationHepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis
Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic
More informationAcute viral hepatitis in Hong Kong: a study of recent incidences
Acute hepatitis in Hong Kong Acute viral hepatitis in Hong Kong: a study of recent incidences TN Chau, ST Lai, JY Lai, H Yuen Acute hepatitis patients admitted to a referral centre from January 1995 through
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationEvidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
Journal of Viral Hepatitis, 20, 8, 369 375 doi:./j.365-2893.20.032.x Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
More informationHepatitis B virus (HBV) infection is a global
VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationKey words:hepatitis B vaccine,anti-hbs,cellular immunity,side effect
Key words:hepatitis B vaccine,anti-hbs,cellular immunity,side effect Table 1 Age and sex of the vaccinees given H-B-VAX male and female vaccinees given H-B-VAX. Fig.1 Comparison of anti-hbs development
More informationVaccine 28 (2010) Contents lists available at ScienceDirect. Vaccine. journal homepage:
Vaccine 28 (2010) 730 736 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Persistence of antibodies and immune memory to hepatitis B vaccine 20 years
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationDynamic analysis of lymphocyte subsets of peripheral blood in patients with acute self-limited hepatitis B
Vol.2, No.7, 736-741 (2010) doi:10.4236/health.2010.27112 Health Dynamic analysis of lymphocyte subsets of peripheral blood in patients with acute self-limited hepatitis B Bo Liu, Jun Li*, Yaping Han,
More informationHepatitis B virus (HBV) is a significant cause of
Secular Trend of the Viral Genotype Distribution in Children With Chronic Hepatitis B Virus Infection After Universal Infant Immunization Wan-Hsin Wen, 1,6,7 Huey-Ling Chen, 1,2 Yen-Hsuan Ni, 1 Hong-Yuan
More information